Skip to main content
J

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 9 across all filing types
Latest filing 2026-04-17 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司独立董事2025年度述职报告（刘卫）（1）
Governance Information Classification · 1% confidence The document is a standalone annual performance report by an independent director (述职报告) detailing governance activities, meeting attendance, committee work, oversight of financial reporting, and protection of shareholder rights. It is not a full annual financial report, earnings release, or announcement of a board change, but rather a governance-focused disclosure. Therefore it best fits the Governance Information category (Code: CGR).
2026-04-17 Chinese
江苏四环生物股份有限公司关于召开2025年年度股东会通知
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a notice to convene the 2025 Annual General Meeting, containing detailed meeting logistics, agenda items, voting procedures, and a proxy form. It is sent to shareholders to provide information and solicit votes/proxies, which matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-17 Chinese
江苏四环生物股份有限公司关于2025年度拟不进行利润分配的专项说明
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement by Jiangsu Sihuan Bio Co., Ltd. regarding its 2025 profit distribution plan, explicitly stating that no cash dividend will be paid, no bonus shares will be issued, and no capital reserve transfer will take place. It covers the board resolution, audited net profit figures, unallocated profit balances, and regulatory compliance for dividend distribution. This matches the definition of a Notice of Dividend Amount (Code: DIV).
2026-04-17 Chinese
江苏四环生物股份有限公司营业收入扣除事项的专项审核报告
Audit Report / Information Classification · 1% confidence The document is a standalone "专项审核报告" (special audit report) issued by an independent accounting firm (China Audit Asia Pacific) for Jiangsu Sihuan Bio Co., Ltd.'s 2025 operating revenue deduction items. It is not a full annual or interim financial report but rather a specific audit opinion and detailed schedules on revenue deductions, fitting the definition of Audit Report / Information (excluding full Annual Reports). Therefore, it matches the AR category.
2026-04-17 Chinese
江苏四环生物股份有限公司董事会对独立董事独立性自查情况的专项报告
Governance Information Classification · 1% confidence The document is a board-issued special opinion on the independence of its independent directors, citing corporate governance rules and stock exchange listing rules. It is not announcing a board change, share transaction, or reporting financial results; rather, it is a governance-related statement on board practices. This best fits the Governance Information category (CGR).
2026-04-17 Chinese
江苏四环生物股份有限公司独立董事2025年度述职报告（王莉）
Governance Information Classification · 1% confidence The document is the 2025 annual performance report by an independent director, detailing governance activities, attendance at board and committee meetings, independence declarations, and oversight of financial reporting and internal controls. It is not an announcement of a report, not a change in board composition, and not a financial or audit report. It falls under corporate governance disclosures on board practices. Therefore, it is classified as Governance Information (CGR).
2026-04-17 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.